CONTENTS

Issue 91 | February 2020

In association with

Horizon 2020

What's next for the EU's flagship pharma projects funded by Horizon 2020?

Drug pricing

The US is considering price-matching with the rest of the developed world

Q&A: testing

Valisure is taking an unusual approach to ensure the quality of the drugs it distributes

drug development

What does ‘ageing’ mean when it comes to drug development?

Drugs in space

NASA funded projects are looking for ways to protect health during deep space missions

Approvals

The resurrection of aducanumab has raised questions about the drugs efficacy 

rare diseases

How is big pharma addressing rare conditions like EDS?

access to medicine

What is pharma's role in improving global access to medicine? 

IMDP

Turning attention towards patient benefits with IDMP data standards implementation

02/24/2024 00:26:53
  • Home | EDS: Treating a medical zebra
  • Scandinavian Health Ltd
  • Editorial
  • Emirates SkyCargo
  • Contents
  • Nolato Company Insight
  • Nolato
  • News
  • The pharma industry briefing
  • Subcuject Company Insight
  • Subcuject
  • Horizon 2020: a look back at flagship EU pharma projects
  • Sanofi
  • Sky high: should US drug prices fall in-line with the rest of the world?
  • Nipro Pharmapackaging
  • Q&A: talking drug quality with Valisure, the first analytical pharmacy
  • Nemera
  • What does ‘ageing’ mean when it comes to drug development?
  • Swiss WorldCargo
  • Manufacturing medicines in space: how astronauts will make their own drugs
  • Mimotopes
  • Aducanumab’s surprising revival: how an Alzheimer’s drug came back from the dead
  • Molnar Company Insight
  • Molnar-Institute
  • Ehlers-Danlos syndrome: The zebra in the room
  • Kugelmeiers
  • Stop ignoring the two billion: pharma’s role in expanding access to medicine
  • Skyepharma
  • IDMP: turning attention to patient benefits
  • Deals in brief powered by GlobalData
  • The key list powered by GlobalData
  • Events
  • Next issue
01/24/2020 00:00:00